Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Equity Average (2020 - 2023)

Historic Equity Average for Terns Pharmaceuticals (TERN) over the last 4 years, with Q3 2023 value amounting to $266.3 million.

  • Terns Pharmaceuticals' Equity Average rose 6595.77% to $266.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $266.3 million, marking a year-over-year increase of 6595.77%. This contributed to the annual value of $218.6 million for FY2022, which is 92012.51% up from last year.
  • Latest data reveals that Terns Pharmaceuticals reported Equity Average of $266.3 million as of Q3 2023, which was up 6595.77% from $280.9 million recorded in Q2 2023.
  • In the past 5 years, Terns Pharmaceuticals' Equity Average ranged from a high of $282.3 million in Q1 2023 and a low of -$118.6 million during Q4 2020
  • For the 4-year period, Terns Pharmaceuticals' Equity Average averaged around $124.6 million, with its median value being $163.3 million (2021).
  • Over the last 5 years, Terns Pharmaceuticals' Equity Average had its largest YoY gain of 32587.48% in 2022, and its largest YoY loss of 2299.87% in 2022.
  • Over the past 4 years, Terns Pharmaceuticals' Equity Average (Quarter) stood at -$118.6 million in 2020, then skyrocketed by 240.13% to $166.2 million in 2021, then skyrocketed by 38.55% to $230.3 million in 2022, then rose by 15.62% to $266.3 million in 2023.
  • Its Equity Average was $266.3 million in Q3 2023, compared to $280.9 million in Q2 2023 and $282.3 million in Q1 2023.